Myelin Repair Foundation Overview
Target demographics: multiple sclerosis patients, people interested in speeding up research and development of treatments for diseases
The Myelin Repair Foundation (MRF) is the world’s largest research organization exclusively focused on developing the next generation of treatments for multiple sclerosis — myelin repair. Myelin repair is the only current research approach that has the potential to actually repair nerve damage and halt the progress of multiple sclerosis.
What sets us apart from other multiple sclerosis research organizations is our aggressive Accelerated Research Collaboration™ (ARC™) model. The model is organized around one principle — to get a safe and effective myelin repair treatment to patients as quickly as humanly possible. Today we are on track toward the first myelin repair phase one clinical trial by 2014.
With its innovative model for medical research, its narrow focus, and its five-year timeline, the Myelin Repair Foundation is on track toward achieving its goal to license at least one myelin repair drug target by 2009.